107 related articles for article (PubMed ID: 12689658)
1. Intravenous and oral pharmacokinetic study of BCX-1777, a novel purine nucleoside phosphorylase transition-state inhibitor. In vivo effects on blood 2'-deoxyguanosine in primates.
Kilpatrick JM; Morris PE; Serota DG; Phillips D; Moore DR; Bennett JC; Babu YS
Int Immunopharmacol; 2003 Apr; 3(4):541-8. PubMed ID: 12689658
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and pharmacodynamics of peldesine (BCX-34), a purine nucleoside phosphorylase inhibitor, following single and multiple oral doses in healthy volunteers.
Viegas TX; Omura GA; Stoltz RR; Kisicki J
J Clin Pharmacol; 2000 Apr; 40(4):410-20. PubMed ID: 10761169
[TBL] [Abstract][Full Text] [Related]
3. Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H)--a novel potent and orally active immunosuppressive agent.
Bantia S; Miller PJ; Parker CD; Ananth SL; Horn LL; Kilpatrick JM; Morris PE; Hutchison TL; Montgomery JA; Sandhu JS
Int Immunopharmacol; 2001 Jun; 1(6):1199-210. PubMed ID: 11407314
[TBL] [Abstract][Full Text] [Related]
4. Mechanism of inhibition of T-acute lymphoblastic leukemia cells by PNP inhibitor--BCX-1777.
Bantia S; Ananth SL; Parker CD; Horn LL; Upshaw R
Int Immunopharmacol; 2003 Jun; 3(6):879-87. PubMed ID: 12781704
[TBL] [Abstract][Full Text] [Related]
5. Potent orally bioavailable purine nucleoside phosphorylase inhibitor BCX-4208 induces apoptosis in B- and T-lymphocytes--a novel treatment approach for autoimmune diseases, organ transplantation and hematologic malignancies.
Bantia S; Parker C; Upshaw R; Cunningham A; Kotian P; Kilpatrick JM; Morris P; Chand P; Babu YS
Int Immunopharmacol; 2010 Jul; 10(7):784-90. PubMed ID: 20399911
[TBL] [Abstract][Full Text] [Related]
6. Synthesis of labeled BCX-4208, a potent inhibitor of purine nucleoside phosphorylase.
Kamath VP; Juarez-Brambila JJ; Morris PE
Drug Test Anal; 2009 Mar; 1(3):125-7. PubMed ID: 20355185
[TBL] [Abstract][Full Text] [Related]
7. A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine).
Gandhi V; Kilpatrick JM; Plunkett W; Ayres M; Harman L; Du M; Bantia S; Davisson J; Wierda WG; Faderl S; Kantarjian H; Thomas D
Blood; 2005 Dec; 106(13):4253-60. PubMed ID: 16131572
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and pharmacokinetic and pharmacodynamic evaluation of the forodesine HCl analog BCX-3040.
Kezar HS; Kilpatrick JM; Phillips D; Kellogg D; Zhang J; Morris PE
Nucleosides Nucleotides Nucleic Acids; 2005; 24(10-12):1817-30. PubMed ID: 16438050
[TBL] [Abstract][Full Text] [Related]
9. [Tight binding transition state analogues of purine nucleoside phosphorylase--meaning, design and properties].
Lewandowicz A
Postepy Biochem; 2004; 50(3):218-27. PubMed ID: 15822751
[No Abstract] [Full Text] [Related]
10. Purine nucleoside phosphorylase inhibitors in T-cell malignancies.
Bantia S; Kilpatrick JM
Curr Opin Drug Discov Devel; 2004 Mar; 7(2):243-7. PubMed ID: 15603259
[TBL] [Abstract][Full Text] [Related]
11. The biochemistry and pharmacology of PD 116124 (8-amino-2'-nordeoxyguanosine), an inhibitor of purine nucleoside phosphorylase (PNP).
Dong MK; Scott ME; Schrier DJ; Suto MJ; Sircar JC; Black A; Chang T; Gilbertsen RB
J Pharmacol Exp Ther; 1992 Jan; 260(1):319-26. PubMed ID: 1530976
[TBL] [Abstract][Full Text] [Related]
12. Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects.
Ramael S; De Smedt F; Toublanc N; Otoul C; Boulanger P; Riethuisen JM; Stockis A
Clin Ther; 2006 May; 28(5):734-44. PubMed ID: 16861095
[TBL] [Abstract][Full Text] [Related]
13. Disposition and safety of zonisamide after intravenous and oral single dose and oral multiple dosing in normal hound dogs.
Boothe DM; Perkins J
J Vet Pharmacol Ther; 2008 Dec; 31(6):544-53. PubMed ID: 19000278
[TBL] [Abstract][Full Text] [Related]
14. Inhibitors of purine nucleoside phosphorylase: effects of 9-deazapurine ribonucleosides and synthesis of 5'-deoxy-5'-iodo-9-deazainosine.
Stoeckler JD; Ryden JB; Parks RE; Chu MY; Lim MI; Ren WY; Klein RS
Cancer Res; 1986 Apr; 46(4 Pt 1):1774-8. PubMed ID: 3081256
[TBL] [Abstract][Full Text] [Related]
15. Comparison of in vivo efficacy of BCX-1777 and cyclosporin in xenogeneic graft-vs.-host disease: the role of dGTP in antiproliferative action of BCX-1777.
Banti S; Miller PJ; Parker CD; Ananth SL; Horn LL; Babu YS; Sandhu JS
Int Immunopharmacol; 2002 Jun; 2(7):913-23. PubMed ID: 12188033
[TBL] [Abstract][Full Text] [Related]
16. Synthesis of a transition state analogue inhibitor of purine nucleoside phosphorylase via the Mannich reaction.
Evans GB; Furneaux RH; Tyler PC; Schramm VL
Org Lett; 2003 Oct; 5(20):3639-40. PubMed ID: 14507192
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
[TBL] [Abstract][Full Text] [Related]
18. Development of transition state analogues of purine nucleoside phosphorylase as anti-T-cell agents.
Schramm VL
Biochim Biophys Acta; 2002 Jul; 1587(2-3):107-17. PubMed ID: 12084452
[TBL] [Abstract][Full Text] [Related]
19. Exploring structure-activity relationships of transition state analogues of human purine nucleoside phosphorylase.
Evans GB; Furneaux RH; Lewandowicz A; Schramm VL; Tyler PC
J Med Chem; 2003 Jul; 46(15):3412-23. PubMed ID: 12852771
[TBL] [Abstract][Full Text] [Related]
20. Purine nucleoside phosphorylase inhibitors: biochemical and pharmacological studies with 9-benzyl-9-deazaguanine and related compounds.
Bennett LL; Allan PW; Noker PE; Rose LM; Niwas S; Montgomery JA; Erion MD
J Pharmacol Exp Ther; 1993 Aug; 266(2):707-14. PubMed ID: 8355201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
